| Wang, Qing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) |
|
|
| Active, not recruiting | 4 | 2500 | RoW | Sodium Oligomannate Capsules | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 04/25 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
CTP-MCVF-003, NCT06226714: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds |
|
|
| Active, not recruiting | 3 | 840 | RoW | MCV4, MPSV4 | CanSino Biologics Inc. | Meningococcal Meningitis | 10/24 | 10/24 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
| Liu, Xiaoqiang |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT04644484: A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety |
|
|
| Completed | 3 | 1000 | RoW | SYN023, A Humanized Anti-Rabies Molecular antibodies cocktails, Human Rabies Immune Globulin (HRIG), Rabies Vaccine, Freeze-dried Rabies Vaccine for Human Use (Vero Cells) | Synermore Biologics (Suzhou) Co., Ltd., Simoon Record Pharma Information Consulting Co., Ltd. | Rabies, Communicable Disease, Virus Diseases, Rhabdoviridae Infections, Mononegavirales Infections, RNA Virus Infections | 06/22 | 12/22 | | |
| Completed | 3 | 1200 | RoW | GR1801, Human Rabies Immunoglobulin(HRIG), Rabies Vaccine | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Rabies Post-exposure Prophylaxis | 09/23 | 09/24 | | |
NCT06331156 / 2022-000708-36: A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants |
|
|
| Completed | 3 | 400 | RoW | HRV PCV-free, Rotarix PCV-free, IPV, Beijing Biological Products Institute Co.,Ltd.'s Inactivated Poliomyelitis Vaccine Made From Sabin Strains (Vero Cells) | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Gastroenteritis | 10/24 | 10/24 | | |
NCT06025695 / 2020-000972-38: Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks |
|
|
| Completed | 3 | 2000 | RoW | GSK's liquid oral live attenuated HRV, Rotarix, PCV-free liquid formulation of GSK's oral live attenuated HRV, Rotarix PCV-free | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Gastroenteritis | 05/24 | 10/24 | | |
NCT04470609: Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years |
|
|
| Completed | 1/2 | 471 | RoW | Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Placebo on a 0- and 28-day schedule | Institute of Medical Biology, Chinese Academy of Medical Sciences, West China Second University Hospital, Yunnan Center for Disease Control and Prevention | COVID-19 | 10/20 | 10/21 | | |
NCT06482216: Correlation of Protection Against Varicella in an Exploratory Study |
|
|
| Not yet recruiting | N/A | 400 | NA | Varicella vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Varicella | 05/27 | 10/28 | | |
NCT04830826: A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China |
|
|
| Recruiting | N/A | 2000 | RoW | Surgeries | The First Affiliated Hospital of Guangzhou Medical University | NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III | 01/24 | 07/24 | | |
| Fang, Xing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT06678373: Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas |
|
|
| Active, not recruiting | 4 | 250 | RoW | Liaoning Chengda Inactivated Japanese Encephalitis Vaccine | Liaoning Chengda Biotechnology CO., LTD | Japanese Encephalitis | 04/26 | 12/26 | | |
BTH-DREAM-PRIDE, NCT04948749: Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial |
|
|
| Recruiting | N/A | 792 | RoW | Drug Eluting Stent implantation, Maurora ® Sirolimus Eluting Stent implantation, Aggressive medical treatment, Dual antiplatelet therapy for 6 months, Risk factor management, Risk factor and life style management, Standard medical treatment, Dual antiplatelet therapy for 3 months | Beijing Tiantan Hospital | ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke, Drug Eluting Stents (DES), Medical Treatment | 12/26 | 12/26 | | |
| Sun, Zhaodan |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Wang, Fubing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT06193941: Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits |
|
|
| Completed | N/A | 400 | RoW | RT-qPCR | Zhongnan Hospital | Bladder Cancer, Urothelial Carcinoma | 12/23 | 12/23 | | |
NCT05575622: Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 200 | RoW | CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection | Zhongnan Hospital | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT05677724: Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment |
|
|
| Recruiting | N/A | 20 | RoW | HBV DNA Sequencing | Fubing Wang | HBV, Primary Liver Cancer | 06/23 | 06/23 | | |
| Zhang, Dongjuan |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT06564116: Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above |
|
|
| Completed | 4 | 612 | RoW | Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli), Recombinant Hepatitis E Vaccine (Escherichia Coli) | Xiamen Innovax Biotech Co., Ltd, Center for Disease Control and Prevention, Fujian | Hepatitis E | 03/24 | 03/24 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Guo, Shicheng |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Tong, Yeqing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT05216484: Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses) |
|
|
| Recruiting | 3 | 480 | RoW | SARS-CoV-2 Vaccine, Inactivated (Vero Cell) | Chinese Academy of Medical Sciences, Hubei Provincial Center for Disease Control and Prevention | SARS-CoV-2 Infection | 10/22 | 12/22 | | |
| Deng, Qiuyun |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Zhang, Ruizhi |
NCT05453487: Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine |
|
|
| Recruiting | 4 | 360 | RoW | coadministration, COVID-19 vaccine, rabies vaccine | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Shaanxi Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd., Changchun Institute of Biological Products Co., Ltd. | COVID-19, Rabies | 10/22 | 06/23 | | |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT05480436: Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population |
|
|
| Recruiting | 4 | 1200 | RoW | coadministration, COVID-19 vaccine, IIV4+PPV23 | China National Biotec Group Company Limited, Hunan Provincial Center for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Guizhou Center for Disease Control and Prevention, Xiangya Hospital of Central South University, Beijing Institute of Biological Products Co Ltd., Chengdu Institute of Biological Products Co.,Ltd., Shanghai Institute Of Biological Products | Hemolysis, COVID-19 | 01/23 | 07/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Zhang, Xiaoshu |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
